2019-03-01 16:00Financial Performance - The company's operating revenue for 2018 was RMB 408.80 million, representing a 35.69% increase compared to RMB 301.28 million in 2017[17]. - The net profit attributable to shareholders for 2018 was RMB 90.29 million, up 36.92% from RMB 65.95 million in 2017[17]. - The net cash flow from operating activities for 2018 was RMB 176.08 million, an increase of 43.25% compared to RMB 122.92 million in 2017[17]. - The total assets at the end of 2018 were RMB 1.14 billion, reflecting a 21.31% increase from RMB 940.87 million at the end of 2017[17]. - The basic earnings per share for 2018 was RMB 0.94, a 17.50% increase from RMB 0.80 in 2017[18]. - The weighted average return on equity for 2018 was 17.99%, a decrease of 2.58 percentage points from 20.57% in 2017[18]. - The total non-recurring gains and losses for 2018 amounted to RMB 18.04 million, compared to RMB 10.50 million in 2017[21]. - The company's net assets attributable to shareholders at the end of 2018 were RMB 651.32 million, a 16.84% increase from RMB 557.44 million at the end of 2017[17]. - The company achieved operating revenue of CNY 408.80 million, a year-on-year increase of 35.69%[63]. - The net profit attributable to shareholders was CNY 108.34 million, reflecting a year-on-year growth of 41.72%[62]. - The gross profit margin for the main business was 53.07%, a decrease of 3.42 percentage points compared to the previous year[64]. Investment and Growth Strategies - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]. - The company aims to expand its market share in preclinical pharmacology and toxicology evaluation services, focusing on innovative drug demands and new technologies[87]. - The company plans to increase its international market presence by enhancing marketing efforts in the US and Europe, including hiring more personnel with overseas experience[88]. - The company intends to enhance its production capacity through mergers, acquisitions, and joint ventures to establish new profit growth points[88]. - The company is exploring potential acquisitions to further enhance its product portfolio and market presence[140]. - The company plans to invest in new business capabilities, particularly in bioanalysis and general toxicology, to enhance its drug evaluation capabilities[92]. Research and Development - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product safety and efficacy[140]. - The R&D department completed over 50 studies in 2018, contributing to a 25% increase in the pipeline of drug candidates[141]. - The company has established a breeding base for non-human primates in Guangxi Wuzhou, covering 565 acres, with a capacity to raise 15,000 primates, enhancing supply during commercial shortages[56]. - The company has invested in over 1,000 advanced equipment and software systems to meet various testing requirements[50]. Market and Industry Trends - The domestic CRO market is expected to grow continuously due to increased investment in drug research and development, supported by national policies[36]. - The implementation of a 60-day review and approval system for drug clinical trials is anticipated to lead to a surge in demand for early clinical services over the next 3-5 years[37]. - The global CRO market size reached $43.09 billion in 2017, with a projected growth rate of over 10% for the next five years[40]. - The domestic CRO market size exceeded RMB 50 billion in 2017, with an expected growth rate of 20%-25% from 2017 to 2022[42]. Corporate Governance and Compliance - The company has committed to avoiding competition with its controlling shareholders and their affiliates, ensuring no direct or indirect competition with its business activities[100]. - The company has implemented an employee stock option and restricted stock incentive plan, which has been approved by the board and supervisory committee[111]. - The company has not reported any significant deficiencies in its internal control systems for the reporting period[161]. - The company maintains a strict governance structure, with a board of nine directors, including three independent directors, and four specialized committees[156]. Environmental Responsibility - The company emphasizes the importance of environmental protection and sustainable development in its operations[119]. - The company aims for 100% compliance in environmental performance and pollutant discharge standards[120]. - The company has implemented a comprehensive environmental management system with regular third-party inspections[119]. - The company has not been listed as a serious polluter by national environmental authorities[119]. Shareholder Information - The total number of ordinary shares increased from 81.8 million to 114.99 million, reflecting a change of 33.19 million shares[123]. - The top shareholder, Feng Yuxia, holds 32.7033 million shares, representing 28.44% of the total shares, with 16.1899 million shares pledged[131]. - The company has committed to a 36-month lock-up period for shares held by major shareholders after listing[134]. - The company’s stock price was set at 28.31 RMB during the issuance of A shares on April 19, 2018[128]. Financial Management - The company has a total of 418,600 shares granted under stock incentives, which will be unlocked in three phases after the lock-up period[128]. - The company reported a total of 336 million in self-owned funds for the year, with a return rate of 5.25%[117]. - The company achieved a revenue of 73.972 million with a fundraising agreement at a rate of 4.50%[118]. - The company plans to continue its wealth management strategy, with various products maturing in 2019[116].